LIM’S Pharmacy in Springvale, Victoria has taken out the top honours at the Australian Pharmacy Professional conference (APP) on the Gold Coast, having been announced as the 2013 QCPP Pharmacy of the Year. In addition, Lim’s Pharmacy was also the community engagement category winner. “We are very honoured and thankful to all those people and organisations that believed in us and encouraged us to enter,” said owner pharmacist Richard Lim, who accepted the award on behalf of his team. “Lim’s pharmacy is in an extremely diverse area in Melbourne. “From our very early days we have engaged with the different cultural centres as a way of ensuring people in our community have access to information and healthcare. This engagement helps us to understand the needs of our patients and drives our innovation,” Lim added. Meanwhile the other big winners included Gerald Burns Pharmacy Perth, Western Australia, which took out the award for Excellence in Business Management; and Craven’s Pharmacy Perth, Western Australia which won for Innovation in Professional Services. For their efforts, the overall winner and the category winners have shared in a cash prize, and each received a trophy to display in their respective pharmacies, as well as a professional photo shoot. “I am extremely proud of our industry and there is no better showcase of our individual and collective achievements than this rigorously judged and highly respected award,” said the National President of the Guild, Kos Sclavos.
THE NSW Health Care Complaints Commission (HCCC) has prosecuted a complaint against pharmacist Nicholas Fearon before the NSW Civil and Administrative Tribunal, which found him guilty of unsatisfactory professional conduct and professional misconduct, and having been convicted of a criminal offence in NSW, was not a suitable person to hold registration as a pharmacist.
SIGMA Healthcare says 2017/18 was a “challenging year” during which it continued to execute its long term strategy despite declining sales due to softening consumer sentiment and reduced demand for low-margin Hepatitis C drugs.